Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2008

View Archived Issues

PRK-124 improves symptoms of rosacea

Phase I results encouraging for diabetic foot ulcer treatment HO/03/03

CTS-1027 hepatoprotective in bile duct-ligated mice

FDA Approves Recothrom 20,000-IU vial size and co-packaging spray kit

Structural damage limited with add-on denosumab in rheumatoid arthritis patients

Biovitrum and Syntonix dose first hemophilia B patient in novel Factor IXFc trial

CombinatoRx completes enrollment in phase IIb CRx-102 trial

NycoCard CRP test to be used in major study targeting overuse of antibiotics

PsychoGenics and Roche collaborate in neuropsychiatric disorder drug discovery

DSMB recommends continuation of BioMS's MINDSET-01 trial of dirucotide in MS

AlphaRx and USAMRIID enter research and development agreement for nanobiotics

AMAG and 3SBio enter development and commercialization agreement for ferumoxytol in China

Ferring's FE-202158 prevents hypotension in experimental septic shock

Nampt inhibitor FK-866 inhibits lung tumor cell growth in vitro

New antithrombotic agents reported in recent patents

Global phase III bevacizumab and trastuzumab trial in breast cancer commences

Recent Tokuyama patent discloses novel therapeutic agents for nausea

Isotechnika presents final results of the PROMISE trial

Sapacitabine receives EMEA orphan designation for AML and MDS

Avanir reports positive outcome of pharmacokinetic study of Zenvia

Favrille reports disappointing results from phase III registration trial of Specifid in NHL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...